Background/Aims: Ethanol consumption and pathological conditions such as cirrhosis lead to a reduction of hepatic glutathione. Hepatic methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, the major methylating agent, is regulated in vivo by glutathione levels. We have previously shown that nitric oxide inactivates methionine adenosyltransferase in vivo by S-nitrosylation. In this study, we aimed to investigate the regulation by glutathione of methionine adenosyltransferase S-nitrosylation in rat liver. Methods: Rat hepatocytes and whole animals were treated with buthionine sulfoximine, an inhibitor of glutathione synthesis, and methionine adenosyltransferase S-nitrosylation and activity were determined. Results: In hepatocytes, buthionine sulfoximine led to the S-nitrosylation and inactivation of methionhre adenosyltransferase. Restoring glutathione levels in
oMet) synthetase) have all been shown to be S-nitrosylated in vivo. However, little is known about the physiological mechanisms that govern protein S-nitrosylation in vivo or in intact cells. Target proteins may exist in two equilibrium forms -nitrosylated (SNO) and denitrosylated (SH) -, and this equilibrium is thought to be regulated by both the cellular levels of NO donors and the concentration of reduced glutathione (GSH).
Hepatic MAT, a key enzyme of methionine metabolism that converts this amino acid into AdoMet, exists in two forms, which are a homotetramer (MAT I) and a homodimer (MAT III) of a single a subunit of 43.7 kDa molecular weight (6-S) . We have previously demonstrated that increased NO production in the liver, during septic shock, led to the S-nitrosylation and inactivation of hepatic MAT (5) . We have further shown an inactivation of MAT in isolated rat hepatocytes by incubation with S-nitrosoglutathione monoethylester, an NO donor permeable through the plasma membrane (5) . Moreover, MAT I and MAT III, purified from rat liver, are S-nitrosylated and inactivated by a variety of NO-donors (3-morpholinosydnonimine, S-nitroso-N-acetylpenicillamine and S-nitrosoglutathione) (59). The hepatic MAT a subunit contains 10 cysteine residues (10,ll) . inactivation of hepatic MAT by NO donors has been shown to be the result of S-nitrosylation of a single cysteine residue of the a subunit located in position 121 (9) . In vitro, NOmediated hepatic MAT S-nitrosylation and inactivation was reversed by millimolar GSH (5) . In the present study, we directly evaluated the effect of intracellular GSH on MAT III S-nitrosylation and activity in a model of rat hepatocytes treated with buthionine sulfoximine (BSO), a well-known inhibitor of GSH synthesis (12) . We also report here on the role of GSH in the regulation of hepatic MAT III S-nitrosylation and activity in viva
Materials and Methods

Materials
Protease inhibitors (phenylmethylsulfonyl fluoride (PMSF) and benzamidine), ATE L-methionine, DL-dithiothreitol, BSO and GSH were obtained from Sigma (St. Louis, MO, USA); [2-3H] ATP (25.5 Ci/mmol) was from Amersham (Little Chalfton, UK). The cation exchanger, AG 5OW-X4 (200 to 400 mesh), was from Bio-Rad Laboratories (Richmond, CA, USA). DEAE Sephacel and phenyl Sepharose were from Pharmacia (Uppsala, Sweden). 2-Mercaptoethanol was from Merck AG (Darmstadt, Germany), and scintillation fluid Optiphase Hisafe 3 was from Wallac (Loughborough, UK). High-performance liquid chromatography (HPLC) column Aminopropyl Spherisorb for glutathione determination was from Waters (Bedford, MA, USA). Glutathione monoethyl ester (EGSH) was synthesized as previously described (13) .
Isolation and incubation of hepatocytes
Hepatocytes were isolated from normally fed Wistar albino rats (250 g) as described by Castaho et al. (14) . Isolated hepatocytes were incubated as follows: 1 to 4 ml of cell suspension (2X106 cells/ml) were shaken in stopped 20-ml vials at 37°C in the presence of 10 mM glucose. The gas phase was 95% 0, and 5% CO1. After 30 min preincubation, BSO or buffer was added, and cells were incubated for the desired period of time. The suspension of hepatocytes was poured after the indicated periods into precooled, centrifuge tubes and immediately centrifuged for 10 s. Cells were then washed twice in phosphate-buffered saline buffer before being homogenized by 3 cycles of freezing and thawing in 10 mM Tris, 0.3 M sucrose, and 1 mM ethylene glycol-bis(J-aminoethyl ether)-N,N-tetraacetic acid (EGTA) (pH 7.5) containing 0.1% PMSF and 0.1% benzamidine. The cytosol was obtained by centrifugation at 100000 g at 4°C. Cell viability was determined before and after the incubation by the Trypan blue exclusion test. MAT III activity and MAT III S-nitrosylation were analyzed in this last supernatant as described below. Only cell preparations with a viability greater than 85% were used. All animals were treated humanely, and study protocols were in compliance with our institution's guidelines for the use of laboratory animals.
BSO treatment
Animals received intraperitoneal injections of BSO (4 mmohkg) or saline at 8 a.m. as previously reported (13) . Samples were collected 2 h later, after the administration of BSO. Liver samples were removed and quickly freeze-clamped in liquid nitrogen. Livers were homogenized in 4 volumes of 10 mM TrislHCl (pH 7.5), containing 0:3 M sucrose, 1 mM EGTA, 0.1% PMSF, and 0.1% benzamidine. The homogenate was centrifuged for 20 min at 10000 g at 4°C; the supernatant was again centrifuged for 1 h at 100000 g. MAT III activity and MAT III S-nitrosylation were analyzed in this last supernatant as described below.
GSH and oxidized glutathione measurements
GSH and oxidized glutathione (GSSG) content was measured by high-performance liquid chromatography according to the method described by Reed et al. (15) . Briefly, 200 ~1 of the cytosolic fraction obtained as indicated above was immediately derivatized using lfluoro-2,4-dinitrobenzene. Samples were then chromatographed on a 3-aminopropyl-Spherisorb, 20X4.6 mm, 5 pm HPLC column, equilibrated in 80% methanol. Elution was performed with 0.5 M sodium acetate in 64% methanol and followed at 365 nm. Analysis of the chromatogram was performed with Beckman System Gold software.
Cytosolic nitrite and nitrate measurements
Nitrite and nitrate were-measured using a NOA 280 chemiluminiscence detector following the method recommended by Sievers (16) . Cytosolic nitrite and nitrate were reduced to NO by incubation with glacial acetic acid containing 350 mM INa or 1 N HCl containing 50 mM VC13, respectively. The resulting NO was measured by the chemiluminescence derived from its reaction with ozone (16) .
Determination of MAT III S-nitrosylation and activity
To measure the S-nitrosylation of MAT III in intact hepatocytes, the protein was purified from the cytosolic fraction of 4 ml of cell suspension (2X lo6 cells/ml) after incubation with the indicated reagents as described previously (5) . Briefly, the cytosol was loaded onto a 2-ml column of DEAE Sephacel equilibrated in a buffer containing 10 mM HEPES, 10 mM MgS04, and 1 mM ethylendiaminetetracetic acid (EDTA) (pH 7.5) (buffer A). The column was washed with 10 volumes of buffer A containing 100 mM KC1 before elution with 2 ml of buffer A containing 200 mM KCl. The eluted enzyme was then chromatographed in a l-ml phenyl Sepharose column equilibrated in buffer A with 200 mM KCl, and then with 10 volumes of 10 mM HEPES and 1 mM EDTA (pH 7.5). Dimethyl sulfoxide (DMSO) is commonly used to elute MAT III from the phenyl Sepharose column (17) . Because DMSO interfered with the NO detection, the resin containing MAT III protein was directly incubated with 2.2 mM HgCla, and the amount of NO released was measured using a Sievers NOA 280 nitric oxide analyzer as described above. Standard curves were generated with known concentrations of S-nitrosoglutathione prepared according to Ruiz et al. (5) . As previously reported (S), the purity of MAT III bound to the phenyl Sepharose column was greater than 90%, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. To determine the recovery of S-nitrosylated MAT III purified by this procedure, a sample of MAT III, purified from rat liver as described previously (11) was reacted in vitro with 100 PM GSNO as described by Ruiz et al. (5), and the number of S-nitrosothi01s (SNO) groups incorporated per milligram of protein was determined in an aliquot (5) . The rest of the S-nitrosylated enzyme was added to a freshly prepared homogenate of hepatocytes. MAT III was then purified and the number of SNO groups was determined as mentioned above. The recovery of SNO groups into MAT III was between 80% to 90%. To measure S-nitrosylation of MAT III in liver, the protein was purified from the cytosolic fraction of about 0.2 g of liver and the number of SNO groups incorporated per milligram of protein was determined as described above for hepatocytes. TO measure the activity of MAT III in the cytosol derived from intact hepatocytes or liver samples, the enzyme was purified, as mentioned above, by DEAE Sephacel and phenyl Sepharose chromatography. The enzyme activity was then measured, as described by Cabrero et al. (18) , by directly incubating the phenyl Sepharose resin containing MAT III with saturating concentrations of methionine and ATP (5 mM each) in the absence of any reducing agent. Total MAT activity was determined according to Lbrero et al. (18) in the presence of saturating concentrations of m onine and ATP and in the absence of any reducing agent using the cytosolic extracts prepared as described above.
Statistics
The data are the mean?SEM of at least three independent experiments. Statistical significance was estimated with Student's t-test. A p-value of less than 0.05 was considered significant.
Results
MAT S-nitrosylation in isolated rat hepatocytes
BSO is a well-known permeable inhibitor of GSH synthesis which inhibits the enzyme y-glutamyl-cysteine synthetase, the first step in GSH synthesis from cysteine (12) . We therefore tested the ability of BSO to reduce GSH levels in isolated rat hepatocytes and its effect on MAT III S-nitrosylation and activity. As expected, the addition of 10 mM BSO to isolated rat hepatocytes induced a time-dependent depletion of total intracellular glutathione (GSH plus GSSG) (Fig.  1) . Thus, after 60 min incubation with BSO the intracellular levels of glutathione were reduced by about 50% as compared to control hepatocytes ( Fig. 1) . At the concentration of BSO used in the present experiments, this molecule had no effect on the ratio GSH/ GSSG (about 100) (data not shown). i'he latter is important since GSSG has been previously shown to in- Time (min) 
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hibit both MAT I and MAT III purified from rat liver (17) . The addition of BSO to isolated rat hepatocytes also induced a time-dependent intracellular accumulation of nitrite plus nitrate (NOx), the inactive metabolites of NO (Fig. 2) . Thus, after 60 min in the presence of BSO the intracellular levels of NOx increased about 3-fold (Fig. 2) . BSO had no effect on the expression in hepatocytes of the inducible NO synthase (iNOS) gene or in the levels of iNOS protein, analyzed by Northern and Western blot, respectively (data not shown). No significant lysis of hepatocytes was observed after incubation with 10 mM BSO under the present conditions (data not shown).
The addition of 10 mM BSO to a suspension of isolated rat hepatocytes induced a time-dependent increase in the S-nitrosylation of MAT III (Fig. 3) . Thus, after 60 min incubation in the presence of BSO the number of SNO groups incorporated into MAT III increased about 7-fold (about 2 sites per MAT subunit) with respect to cells incubated in the absence of BSO (Fig. 3) . As shown in S-nitrosylation led to a reduction of the activity of the enzyme of about 80%. When hepatocytes were incubated with 0.5 mM NG-nitro-L-arginine (L-NNA), an inhibitor of NOS activity with higher affinity for the constitutive enzyme, the increase in the cellular content of NOx in response to BSO was abolished and, as expected, no effect of this agent on MAT III S-nitrosylation and inactivation was detected (data not shown). Incubation of hepatocytes with 0.5 mM L-NNA had no effect on the cellular depletion of GSH induced by BSO (data not shown).
To demonstrate that the effect of BSO on MAT III S-nitrosylation and activity was mediated by the depletion of intracellular GSH caused by this molecule, we tested the effect of restoring GSH levels on MAT III S-nitrosylation and activity in cells pre-treated with BSO. To restore cellular GSH levels, after being depleted by BSO administration, we used EGSH a wellknown permeable derivative of GSH, which, upon its entrance to the cell, is converted into GSH and ethanol (12) . The addition of 5 mM EGSH to isolated rat hepatocytes pre-treated for 60 min with 10 mM BSO increased, within the following 60 min, the intracellular 
. A model for cysteine S-nitrosylation as a control switch to regulate hepatic methionine adenosyltransferase (MAT) activity. In this model, hepatic MAT a subunits exist in two forms in equilibrium, nitrosylated (SNO, inactive) and denitrosylated (SH, active), which are regulated by both the intracellular levels of nitric oxide (NO) and glutathione (GSH). Cysteine 121 is the residue of the hepatic MAT a subunit involved in the reaction with NO donors and GSH.
GSH levels to reach values comparable to those observed in control cells treated with the EGSH (Fig. 1) . This increase in intracellular GSH resulted in loss of most of the NO groups incorporated into MAT III as a consequence of the addition of BSO (Fig. 3) , and returned the activity of the enzyme to that of control hepatocytes (Fig. 4) . These results indicate that MAT III S-nitrosylation in isolated rat hepatocytes is a reversible process regulated by both the intracellular concentration of NO donors and GSH, and that conditions that resulted in loss of SNO groups reversed the inactivation of the enzyme. Nitrite and nitrate (NOx) are the inactive end-products of NO metabolism. When EGSH was added to hepatocytes pretreated with BSO, the increase in the cellular content of NOx had already reached a plateau (Fig. 2) , indicating that no further NO was generated by the hepatocytes in response to this agent. Consequently, the administration of EGSH to hepatocytes pre-treated with BSO had no effect on the cellular content of NOx (Fig. 2) .
In vivo S-nitrosylation of hepatic MAT
Hepatic MAT activity is known to be regulated in vivo by GSH levels (13) . We have previously demonstrated that the intraperitoneal injection of BSO to rats led to depletion of GSH and inactivation of hepatic MAT. We have therefore determined whether BSO-induced hepatic MAT inactivation in vivo was also mediated by MAT S-nitrosylation. In vivo S-nitrosylation of rat liver MAT III was analyzed 2 h after the intraperitoneal injection of BSO (4 mmol/kg). As previously reported (5), liver MAT III purified from control animals contained SNO groups (8 nmol per milligram MAT subunit; about 0.4 sites per MAT subunit) (Fig. 5) . Administration of BSO to rats induced a 3.Cfold increase in S-nitrosylation of MAT III (about 1.3 sites per MAT subunit) (Fig. 5) . As previously reported (13), hepatic glutathione levels and total MAT activity decreased by about 60% and 50%, respectively, in animals treated with BSO (data not shown). MAT III activity decreased also by about 50% in response to BSO treatment (data not shown). Under the present conditions, the hepatic ratio of GSWGSSG did not change significantly with BSO injection (data not shown). No effect on hepatic or serum NOx levels was observed after BSO administration (data not shown). The simultaneous administration of BSO (4 mmol/kg) and EGSH (7.5 mmol/kg) prevented the effect of BSO on liver MAT III S-nitrosylation (Fig. 5) . As previously reported (13) the simultaneous administration to rats of EGSH also prevented the effect of BSO on hepatic GSH levels and MAT activity (data not shown). These results demonstrate that also in vivo the inactivation of hepatic MAT induced by BSO is mediated by Snitrosylation of the enzyme.
Discussion
We have previously implicated NO as a regulator of liver MAT. Our data show an inactivation of hepatic MAT by NO produced during septic shock (9) or hypoxia (19) whereas inhibition of NO synthase, by NGnitro-L-arginine-methylester, prevented hepatic MAT inactivation in response to hypoxia (19). We have further shown that incubation of isolated rat hepatocytes with S-nitrosoglutathione monoethylester induced a dose-dependent inactivation of MAT that was reversed by removing the NO donor from the cell suspension (5) . Moreover, the activity of MAT I and MAT III, purified from rat liver, was inactivated by incubation with NO donors (3-morpholinosydnonimine, S-nitroso-N-acetylpenicillamine and S-nitrosoglutathione), a process that was reversed by GSH (5,9). Recently we were able to demonstrate that S-nitrosylation of hepatic MAT led to inactivation of the enzyme, both in vitro and in vivo (5) . Finally, inactivation of hepatic MAT by NO donors has been shown to be the result of S-nitrosylation of a cysteine residue of the a subunit located in position 121 (9) .
The role of GSH in controlling hepatic MAT activity has been previously demonstrated. Thus, conditions that led to hepatic GSH depletion, like BSO (13) or carbon tetrachloride (20) in rats and alcoholic cirrhosis in humans (21), were accompanied by a marked reduction in hepatic MAT activity (13, 20, 22, 23) . In the present study, we directly evaluated the role of GSH on MAT III S-nitrosylation and activity in isolated rat hepatocytes and in an in viva rat model. Whereas MAT III can be readily isolated in the absence of dithiothreitol in the buffers used for purification to avoid the loss of SNO groups in the enzyme, by using the procedure mentioned in Materials and Methods, no method is yet available that permits the rapid isolation of MAT I. Moreover, when MAT I was purified by conventional procedures (17) the enzyme lost the SNO groups. Therefore, only the effect of GSH on MAT III S-nitrosylation was studied. The experimental model of isolated rat hepatocytes eliminates the influence of other organs and cells on liver responses. Using this model, we have observed an increased S-nitrosylation and inactivation of MAT III during BSO-mediated GSH depletion. Incubation of rat hepatocytes with BSO was also accompanied by a moderate increase in the cellular concentration of NOx that was not caused by an increase in iNOS protein levels, but probably by the activation of pre-existing NOS. Since the collagenase method used to isolate rat hepatocytes has been shown to induce the expression of iNOS (24,25), the increase in NOx content induced by BSO may be due to the activation of this pre-existing iNOS or of any other class of pre-existing NOS. This hypothesis is supported by the finding that incubation of hepatocytes with the NOS inhibitor L-NNA prevented the increase in the cellular content of NOx induced by BSO and, consequently, prevented the S-nitrosylation and inactivation of MAT III induced by this agent. These results suggested that the increase in the production of NO and the decrease in GSH levels could be the cause of MAT III S-nitrosylation and inactivation. This point was further supported by the finding that the addition of EGSH to hepatocytes pre-treated with BSO restored GSH levels, removed most of the SNO groups incorporated into MAT III, and reactivated the enzyme. These results and our previous observations indicate that hepatic MAT a subunits exist in two forms in equilibrium, nitrosylated (inactive) and denitrosylated (active), which are regulated by both the cellular levels of NO and GSH (Fig. 6) .
We had previously demonstrated that the administration of BSO to rats led to hepatic GSH depletion and MAT inactivation and that this effect in vivo of BSO could be prevented by the simultaneous administration of EGSH (13) . Our present results show that in vivo, when rats were treated with BSO, the reduction in GSH levels induced by this molecule was enough to induce an increased S-nitrosylation of hepatic MAT III. This point was further supported by the finding that the addition of EGSH to rats prevented not only the effect of BSO on GSH levels and MAT activity (13) , but also the increase in MAT III S-nitrosylation induced by this molecule. Whereas BSO induced a 7-fold increase in MAT III S-nitrosylation in isolated rat hepatocytes, the magnitude of this effect in vivo was only 3.4-fold. These differences could be due to the finding that in isolated rat hepatocytes, but not in whole animals, BSO induced not only a depletion of GSH but also an increase in the cellular content of NOx. While the reason for these differences between the in vivo and in vitro experiments with respect to the production of NOx remains unclear, the results with whole animals show that the incorporation of NO groups into MAT can be increased by reducing the cellular levels of GSH without necessarily stimulating the synthesis of NO. This is possible if, as depicted in Fig. 6 , the nitrosylated and denitrosylated forms of MAT are in an equilibrium regulated by both the cellular levels of NO donors and GSH. A consequence of this model is that NO does not need to exhaust the GSH pool to react with specific SH residues of proteins, but the reaction depends on the reactivities of the low-mass NO donors and the GSH content.
According to this model, in resting hepatocytes, at low concentrations of NO donors, the rate of addition of NO groups to MAT will be slower than the rate of denitrosylation of the enzyme driven by the high intracellular concentration of GSH (millimolar) and, as a consequence, the enzyme a subunits will be mainly in the denitrosylated form and therefore in their active conformation. If the cellular concentration of GSH decreases, as during the inhibition of its synthesis by BSO, the rate of MAT denitrosylation will also be reduced and a new steady state will be reached where more MAT (r subunits will contain SNO groups, switching the enzyme to its inactive conformation. Restoring the basal GSH levels would increase the rate of removal of NO groups from MAT, switching the enzyme to the denitrosylated active form. Increased MAT S-nitrosylation and inactivation could also be reached after increasing the cellular concentration of NO donors but without affecting the GSH content, as during septic shock (9, 26, 27) , or by simultaneously increasing the synthesis of NO and reducing GSH levels, as during hypoxia (19,28). In both cases, returning the GSH concentration and/or NO synthesis to pre-stimulation levels would result in the removal of NO groups from MAT a subunits and in the reactivation of the enzyme.
The finding that a reduction in the hepatic GSH levels can lead to protein S-nitrosylation in the absence of increased NO synthesis is of general interest since a number of conditions and agents that induce hepatic GSH depletion, like ethanol consumption, apoptosis, paracetamol and carbon tetrachloride administration, and pathological conditions such as cirrhosis (20,21,29-41), may lead to the S-nitrosylation of a variety of proteins, in addition to MAT, thus contributing to the physiopathological effect of these various conditions and agents.
